Credit Suisse Group reissued their buy rating on shares of Pfizer (NYSE:PFE) in a research report released on Monday, Borsen Zeitung reports. They currently have a $48.00 price objective on the biopharmaceutical company’s stock.

PFE has been the topic of several other reports. UBS Group cut Pfizer from a buy rating to a neutral rating in a research report on Wednesday, January 23rd. ValuEngine cut Pfizer from a buy rating to a hold rating in a research report on Thursday, January 24th. Zacks Investment Research cut Pfizer from a hold rating to a sell rating in a research report on Friday, January 25th. Argus upgraded Pfizer from a hold rating to a buy rating and set a $55.00 price target on the stock in a research report on Thursday, January 31st. Finally, Cantor Fitzgerald reiterated a buy rating and set a $53.00 price target on shares of Pfizer in a research report on Tuesday, February 19th. Fourteen research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock presently has a consensus rating of Hold and an average target price of $45.78.

Shares of Pfizer stock opened at $41.35 on Monday. Pfizer has a 52-week low of $34.71 and a 52-week high of $46.47. The stock has a market capitalization of $246.39 billion, a P/E ratio of 13.78, a PEG ratio of 2.40 and a beta of 0.71. The company has a current ratio of 1.57, a quick ratio of 1.33 and a debt-to-equity ratio of 0.52.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, April 30th. The biopharmaceutical company reported $0.85 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.75 by $0.10. Pfizer had a return on equity of 26.54% and a net margin of 21.31%. The business had revenue of $13.12 billion for the quarter, compared to analysts’ expectations of $13.01 billion. During the same period in the previous year, the business posted $0.77 EPS. The firm’s quarterly revenue was up 1.6% compared to the same quarter last year. As a group, sell-side analysts forecast that Pfizer will post 2.89 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 10th will be issued a dividend of $0.36 per share. This represents a $1.44 annualized dividend and a dividend yield of 3.48%. The ex-dividend date is Thursday, May 9th. Pfizer’s payout ratio is 48.00%.

In other news, EVP Dawn Rogers sold 15,002 shares of the business’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $42.98, for a total transaction of $644,785.96. Following the completion of the transaction, the executive vice president now owns 28,722 shares of the company’s stock, valued at $1,234,471.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mikael Dolsten sold 149,553 shares of the business’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $43.55, for a total value of $6,513,033.15. Following the transaction, the insider now directly owns 390,097 shares of the company’s stock, valued at approximately $16,988,724.35. The disclosure for this sale can be found here. Insiders have sold 288,726 shares of company stock valued at $12,534,617 in the last three months. 0.09% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently modified their holdings of the company. OppenheimerFunds Inc. boosted its stake in Pfizer by 32.2% in the third quarter. OppenheimerFunds Inc. now owns 6,890,372 shares of the biopharmaceutical company’s stock worth $303,659,000 after buying an additional 1,678,438 shares in the last quarter. Viridian Ria LLC boosted its stake in Pfizer by 0.9% in the fourth quarter. Viridian Ria LLC now owns 30,859 shares of the biopharmaceutical company’s stock worth $1,327,000 after buying an additional 280 shares in the last quarter. Prio Wealth Limited Partnership boosted its stake in Pfizer by 3.2% in the third quarter. Prio Wealth Limited Partnership now owns 1,039,655 shares of the biopharmaceutical company’s stock worth $45,817,000 after buying an additional 32,071 shares in the last quarter. Rehmann Capital Advisory Group boosted its stake in Pfizer by 1.4% in the third quarter. Rehmann Capital Advisory Group now owns 125,426 shares of the biopharmaceutical company’s stock worth $5,528,000 after buying an additional 1,759 shares in the last quarter. Finally, Focused Wealth Management Inc boosted its stake in Pfizer by 160.7% in the third quarter. Focused Wealth Management Inc now owns 83,780 shares of the biopharmaceutical company’s stock worth $3,692,000 after buying an additional 51,644 shares in the last quarter. 69.36% of the stock is owned by institutional investors.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Read More: Outstanding Shares and The Effect on Share Price

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.